Automatic slicing system: Ex-vivo culture normal and cancerous pancreatic tissue

March 24, 2009

Pancreatic cancer is a devastating disease with a very poor prognosis. This warrants the development of novel therapies including gene therapy. Several of these treatments were found to be effective in pre-clinical (animal) models. However, in the subsequent clinical studies in patients the results were disappointing. The discrepancy between pre-clinical models and results seen in patients underscores the need for pre-clinical models that more reliable predict the clinical efficacy.

A research article to be published on March 21,2009 of the World Journal of Gastroenterology addresses this problem and presents a novel model system more comparable to the in vivo situation in patients. Dr. van Geer and his colleagues in the University of Amsterdam have developed a system to culture normal and cancerous pancreatic tissue isolated from resection specimens obtained from patients. They used an automatic slicing system to provide a sufficient number of slices from the minimal amounts of tissue obtained from patients. In contrast to the existing pre-clinical models such as mouse models, this new model does assess the cellular heterogeneity of solid tumors and the accumulation of extracellular matrix that occurs in human tumors.

Although ex-vivo culture of pancreatic tissue has been reported, all existing methods performed poorly with respect to reproducibility and viability. We developed a system to generate slices uniform in size, shape and viability using an automatic precision cutter. These slices can cultured for at least 6 days while retaining viability and functionality. Based on this our model system allows reproducible testing of novel treatment options for pancreatic cancer, including studies to determine the efficacy of gene therapy vectors.

The authors have developed an ex-vivo system that allows processing of minimal amounts of pancreatic tissue from resection specimens. With this method, authors provide thin and viable tissue slices in a sufficient number to compare the efficiency of different gene therapy vectors. In addition, this system can be used to test novel molecular approaches to treat pancreatic cancer. Finally, these slices seem suitable for testing the susceptibility of the cultured cancer to available cytotoxic drugs which will allow to select optimal treatment to prevent re-occurrence .

Pancreatic cancer is a devastating disease and in the last decades only minimal progress has been made and the prognosis of patients suffering from pancreatic cancer remains poor. Lack of reliable pre-clinical model systems impairs the development of novel treatments. In this paper we present an in vitro system using patient material that not only helps to test novel drugs but also seems suitable for tailoring the therapy to provide optimal treatment for patients after resection.

The Academic Medical Center of the University of Amsterdam is one of the major referral centers in The Netherlands for Gastrointestinal Diseases and Cancer. At the department of surgery up to 50 pancreaticoduodenectomies are performed each year.
Reference: van Geer MA, Kuhlmann KFD, Bakker CT, ten Kate FJW, Oude Elferink RPJ, Bosma PJ. Ex-vivo evaluation of gene therapy vectors in human pancreatic (cancer) tissue slices. World J Gastroenterol 2009; 15(11): 1359-1366

Correspondence to: Dr. Piter J Bosma, Liver Center, Academic Medical Center of the University of Amsterdam, Meibergdreef 69/71, 1105 BK Amsterdam, The Netherlands. Telephone: +31-20-5668850 Fax: +31-20-5669190

World Journal of Gastroenterology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to